Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVRX NASDAQ:HYPR NYSE:NSPR NASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$5.03+2.9%$6.75$4.37▼$11.30$129.76M0.8316,972 shs264,367 shsHYPRHyperfine$1.36-4.2%$1.42$0.66▼$2.22$140.96M1.38488,790 shs464,071 shsNSPRInspireMD$0.73+0.1%$1.13$0.72▼$2.93$34.19M0.74180,426 shs121,612 shsRCELAvita Medical$3.91-1.5%$4.39$3.22▼$7.12$122.18M1.87266,189 shs258,701 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx+2.17%-15.87%-6.36%-34.46%-25.34%HYPRHyperfine+1.43%-5.33%-17.92%+24.56%+70.28%NSPRInspireMD-5.95%-21.16%-39.23%-55.80%-70.23%RCELAvita Medical-3.64%-8.94%-9.36%-9.77%-34.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$5.03+2.9%$6.75$4.37▼$11.30$129.76M0.8316,972 shs264,367 shsHYPRHyperfine$1.36-4.2%$1.42$0.66▼$2.22$140.96M1.38488,790 shs464,071 shsNSPRInspireMD$0.73+0.1%$1.13$0.72▼$2.93$34.19M0.74180,426 shs121,612 shsRCELAvita Medical$3.91-1.5%$4.39$3.22▼$7.12$122.18M1.87266,189 shs258,701 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx+2.17%-15.87%-6.36%-34.46%-25.34%HYPRHyperfine+1.43%-5.33%-17.92%+24.56%+70.28%NSPRInspireMD-5.95%-21.16%-39.23%-55.80%-70.23%RCELAvita Medical-3.64%-8.94%-9.36%-9.77%-34.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVRXCVRx 3.00Buy$11.50128.63% UpsideHYPRHyperfine 2.33Hold$1.7831.13% UpsideNSPRInspireMD 3.00Buy$4.50516.44% UpsideRCELAvita Medical 2.33Hold$7.2585.42% UpsideCurrent Analyst Ratings BreakdownLatest NSPR, CVRX, HYPR, and RCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026RCELAvita Medical Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$3.50 ➝ $6.005/13/2026HYPRHyperfine B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/6/2026CVRXCVRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/5/2026NSPRInspireMD Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$4.00 ➝ $3.005/4/2026NSPRInspireMD Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.004/29/2026HYPRHyperfine BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$2.004/21/2026HYPRHyperfine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026CVRXCVRx Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.004/8/2026RCELAvita Medical D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/27/2026RCELAvita Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/19/2026HYPRHyperfine Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVRXCVRx$56.65M2.36N/AN/A$1.50 per share3.35HYPRHyperfine$11.40M11.84N/AN/A$0.42 per share3.24NSPRInspireMD$10.85M3.15N/AN/A$1.83 per share0.40RCELAvita Medical$71.61M1.68N/AN/A($0.55) per share-7.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVRXCVRx-$53.31M-$2.02N/AN/AN/A-89.14%-120.76%-48.38%8/4/2026 (Estimated)HYPRHyperfine-$35.57M-$0.41N/AN/AN/A-226.88%-98.83%-67.09%8/12/2026 (Estimated)NSPRInspireMD-$19.92M-$0.73N/AN/AN/A-413.96%-69.42%-57.68%N/ARCELAvita Medical-$48.59M-$1.57N/AN/AN/A-62.67%N/A-78.92%8/6/2026 (Estimated)Latest NSPR, CVRX, HYPR, and RCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026RCELAvita Medical-$0.35-$0.35N/A-$7.00$18.30 million$19.25 million5/12/2026Q1 2026HYPRHyperfine-$0.09-$0.09N/A-$0.09$3.54 million$3.90 million5/11/2026Q1 2026CVRXCVRx-$0.51-$0.50+$0.01-$0.50$14.49 million$14.77 million3/18/2026Q4 2025HYPRHyperfine-$0.08-$0.06+$0.02-$0.06$5.30 million$5.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVRXCVRxN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ARCELAvita MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVRXCVRx2.0110.208.89HYPRHyperfine0.385.524.90NSPRInspireMDN/A6.396.05RCELAvita MedicalN/A0.470.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVRXCVRx75.27%HYPRHyperfine15.03%NSPRInspireMD44.78%RCELAvita Medical27.66%Insider OwnershipCompanyInsider OwnershipCVRXCVRx13.90%HYPRHyperfine26.33%NSPRInspireMD34.06%RCELAvita Medical2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVRXCVRx16026.54 million22.85 millionOptionableHYPRHyperfine19099.27 million73.13 millionOptionableNSPRInspireMD5046.84 million18.33 millionOptionableRCELAvita Medical13030.78 million29.92 millionOptionableNSPR, CVRX, HYPR, and RCEL HeadlinesRecent News About These CompaniesAvita Medical (NASDAQ:RCEL) Director Purchases $20,800.00 in StockJune 11 at 8:15 AM | insidertrades.comAvita Medical (NASDAQ:RCEL) Director Purchases $41,900.00 in StockJune 10 at 6:10 AM | insidertrades.comAvita Medical (NASDAQ:RCEL) Director Purchases $40,900.00 in StockJune 6, 2026 | insidertrades.comAvita Medical Inc. (NASDAQ:RCEL) Given Consensus Rating of "Hold" by AnalystsJune 5, 2026 | americanbankingnews.comAvita Medical (NASDAQ:RCEL) Director Buys $43,000.00 in StockJune 4, 2026 | insidertrades.comAVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Prepared Remarks TranscriptJune 3, 2026 | seekingalpha.comAVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth TranscriptMay 22, 2026 | seekingalpha.comAVITA Medical to Host Investor Webinar BriefingMay 17, 2026 | globenewswire.comBTIG Reaffirms Their Hold Rating on Avita Medical (RCEL)May 17, 2026 | theglobeandmail.comLake Street upgrades AVITA Medical (RCEL)May 16, 2026 | msn.comAvita (RCEL) Q1 2026 Earnings Call TranscriptMay 15, 2026 | theglobeandmail.comAvita Medical Q1 Earnings Call HighlightsMay 14, 2026 | marketbeat.comAVITA Medical, Inc. (RCEL) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comAVITA Medical Reports First Quarter 2026 Financial ResultsMay 14, 2026 | globenewswire.comAVITA Medical Names Cary Vance as Chief Executive OfficerApril 30, 2026 | globenewswire.comAVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GOApril 29, 2026 | globenewswire.comAVITA Medical to Announce First Quarter 2026 Financial ResultsApril 23, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical Inc. - RCELApril 21, 2026 | globenewswire.comAVITA Medical, Inc. (RCEL) Shareholder/Analyst Call TranscriptApril 16, 2026 | seekingalpha.comAVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn AssociationApril 15, 2026 | globenewswire.comAvita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?April 15, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNSPR, CVRX, HYPR, and RCEL Company DescriptionsCVRx NASDAQ:CVRX$5.03 +0.14 (+2.86%) Closing price 04:00 PM EasternExtended Trading$5.08 +0.05 (+0.99%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Hyperfine NASDAQ:HYPR$1.36 -0.06 (-4.23%) Closing price 04:00 PM EasternExtended Trading$1.38 +0.02 (+1.76%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.InspireMD NYSE:NSPR$0.73 +0.00 (+0.10%) Closing price 04:00 PM EasternExtended Trading$0.74 +0.01 (+0.96%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Avita Medical NASDAQ:RCEL$3.91 -0.06 (-1.51%) Closing price 04:00 PM EasternExtended Trading$3.96 +0.05 (+1.28%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
